News, October 22, 2007 International Approvals: Exelon, Aclasta, Celsentri Europe has approved a new indication for a rivastigmine transdermal system (Exelon Patch), a new indication for ...

Common side effects May include: headache nausea muscle pain fever bone pain fatigue joint pain dizziness diarrhea itching vomiting skin rash This article provides an overview of the prescription ...

To receive full access to Campaign's content including: Unrestricted access to all The Information and The Knowledge content Access to Campaign's in-depth features and coveted reports including ...

Newer additions to this class include Zometa/Aclasta (zoledronic acid, Novartis; approved in 2007 in the US and EU), which has the advantage of convenient once-yearly dosing and high efficacy ...

“Obviously if you give it intravenously once a year, as with zoledronic acid [Aclasta/Reclast; Novartis], or subcutaneously twice a year, as with denosumab, you're going to have much higher ...